NASDAQ : MDWD
MediWound Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 13.3 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 171.71M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 175.90M |
| Enterprise Value | 149.17M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 12.91M |
| Shares Outstanding | 12.91M |
| Shares Change (YoY) | +15.45% |
| Shares Change (QoQ) | +2.58% |
| Owned by Insiders (%) | 2.88% |
| Owned by Institutions (%) | 52.30% |
| Float | 8.87M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.47 |
| Forward PS | 5.02 |
| PB Ratio | 4.82 |
| P/TBV Ratio | 4.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 12.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.32 |
| Quick Ratio | 2.09 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -72.37% |
| Return on Assets (ROA) | -28.59% |
| Return on Invested Capital (ROIC) | -54.81% |
| Return on Capital Employed (ROCE) | -59.55% |
| Weighted Average Cost of Capital (WACC) | 4.54% |
| Revenue Per Employee | $98,041 |
| Profits Per Employee | -$166,769 |
| Employee Count | 121 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 2.52 |
Taxes
| Measure | Value |
|---|
| Income Tax | 142,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.09 |
| 52-Week Price Change | -26.40% |
| 50-Day Moving Average | 13.06 |
| 200-Day Moving Average | 15.24 |
| Relative Strength Index (RSI) | 55.12 |
| Average Volume (20 Days) | 104,038 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.75M |
| Short Previous Month | 1.84M |
| Short % of Shares Out | 15.48% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 24.32 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 11.86M |
| Gross Profit | 1.83M |
| Operating Income | -31.76M |
| Pretax Income | -20.04M |
| Net Income | -20.18M |
| EBITDA | -30.75M |
| EBIT | -31.76M |
| Loss Per Share | -$2.25 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 35.34M |
| Total Debt | 8.61M |
| Net Cash | 26.74M |
| Net Cash Per Share | $2.07 |
| Equity (Book Value) | 35.64M |
| Book Value Per Share | 2.76 |
| Working Capital | 24.41M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -22.14M |
| Capital Expenditures | -6.39M |
| Depreciation & Amortization | 1.01M |
| Net Borrowing | -1.38M |
| Free Cash Flow | -28.53M |
| FCF Per Share | -$2.21 |
Margins
| Measure | Value |
|---|
| Gross Margin | 15.46% |
| Operating Margin | -267.75% |
| Pretax Margin | -168.90% |
| Profit Margin | -170.10% |
| EBITDA Margin | -259.20% |
| EBIT Margin | -267.75% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -15.45% |
| Shareholder Yield | -15.45% |
| Earnings Yield | -16.49% |
| FCF Yield | -16.61% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $30.67 |
| Price Target Difference | 125.10% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 40.56% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 20, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.98 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |